help button home button
AJRCCM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Okazawa, A.
Right arrow Articles by Lotvall, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Okazawa, A.
Right arrow Articles by Lotvall, J.

Am. J. Respir. Crit. Care Med., Vol 155, No. 2, 02 1997, 436-441.

8-Epi-PGF2alpha induces airflow obstruction and airway plasma exudation in vivo

A Okazawa, I Kawikova, ZH Cui, BE Skoogh and J Lotvall
Department of Respiratory Medicine and Allergology, Institute of Heart and Lung Diseases, Goteborg University, Gothenburg, Sweden.

8-Epi-prostaglandin F2alpha (8-epi-PGF2alpha) is an F2-isoprostane formed mainly via noncyclooxygenase pathways in vivo. We investigated whether 8-epi-PGF2alpha has any effect on airflow obstruction and plasma exudation in vivo. Airflow obstruction was quantified by measuring lung resistance (RL) in anesthetized and ventilated guinea pigs, and plasma exudation was quantified by the Evans Blue dye method (20 mg/kg intravenously). Intratracheal instillation of 8-epi-PGF2alpha (1 nmol or 10 nmol) caused dose-related increases in RL. Furthermore, the higher dose of 8-epi-PGF2alpha produced Evans Blue dye extravasation in main bronchi and intrapulmonary airways. A prostanoid TP-receptor antagonist, BAY u3405 (1 mg/kg intravenously), abolished the airway effects of 8-epi-PGF2alpha (10 nmol). A thromboxane A2 (TxA2) synthase inhibitor, OKY-406 (30 mg/kg intravenously), significantly attenuated these effects of 8-epi-PGF2alpha (10 nmol). The level of TxB2, a stable TxA2 metabolite, increased in bronchoalveolar lavage fluid (BALF) after 8-epi-PGF2alpha instillation. We conclude that 8-epi-PGF2alpha causes airflow obstruction and plasma exudation in vivo. This effect may be mediated primarily via prostanoid TP-receptors, and a secondary generation of TxA2 may be involved in part of the airway responses in 8-epi-PGF2alpha in the guinea pig.


This article has been cited by other articles:


Home page
 Am. J. Respir. Crit. Care Med.Home page
L. G. Wood, M. L. Garg, J. L. Simpson, T. A. Mori, K. D. Croft, P. A. B. Wark, and P. G. Gibson
Induced Sputum 8-Isoprostane Concentrations in Inflammatory Airway Diseases
Am. J. Respir. Crit. Care Med., March 1, 2005; 171(5): 426 - 430.
[Abstract] [Full Text] [PDF]

Home page
 FASEB J.Home page
P. MONTUSCHI, P. J. BARNES, and L. J. ROBERTS II
Isoprostanes: markers and mediators of oxidative stress
FASEB J, December 1, 2004; 18(15): 1791 - 1800.
[Abstract] [Full Text] [PDF]

Home page
 Pharmacol. Rev.Home page
P. J. Barnes
Mediators of Chronic Obstructive Pulmonary Disease
Pharmacol. Rev., December 1, 2004; 56(4): 515 - 548.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
P.J. Barnes, S.D. Shapiro, and R.A. Pauwels
Chronic obstructive pulmonary disease: molecular and cellularmechanisms
Eur. Respir. J., October 1, 2003; 22(4): 672 - 688.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
L.G. Wood, P.G. Gibson, and M.L. Garg
Biomarkers of lipid peroxidation, airway inflammation and asthma
Eur. Respir. J., January 1, 2003; 21(1): 177 - 186.
[Abstract] [Full Text] [PDF]

Home page
 J. Appl. Physiol.Home page
N. C. Long, J. Suh, J. D. Morrow, R. H. Schiestl, G. G. K. Murthy, J. D. Brain, and B. Frei
Ozone causes lipid peroxidation but little antioxidant depletion in exercising and nonexercising hamsters
J Appl Physiol, October 1, 2001; 91(4): 1694 - 1700.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
L. J. Janssen
Isoprostanes: an overview and putative roles in pulmonary pathophysiology
Am J Physiol Lung Cell Mol Physiol, June 1, 2001; 280(6): L1067 - L1082.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Cell Mol. Bio.Home page
C. Martin, S. Uhlig, and V. Ullrich
Cytokine-Induced Bronchoconstriction in Precision-Cut Lung Slices Is Dependent upon Cyclooxygenase-2 and Thromboxane Receptor Activation
Am. J. Respir. Cell Mol. Biol., February 1, 2001; 24(2): 139 - 145.
[Abstract] [Full Text]

Home page
 J. Pharmacol. Exp. Ther.Home page
L. J. Janssen, M. Premji, S. Netherton, A. Catalli, G. Cox, S. Keshavjee, and D. J. Crankshaw
Excitatory and Inhibitory Actions of Isoprostanes in Human and Canine Airway Smooth Muscle
J. Pharmacol. Exp. Ther., November 1, 2000; 295(2): 506 - 511.
[Abstract] [Full Text]

Home page
 Am. J. Respir. Crit. Care Med.Home page
G. CIABATTONI, G. DAVI, M. COLLURA, L. IAPICHINO, F. PARDO, A. GANCI, R. ROMAGNOLI, J. MACLOUF, and C. PATRONO
In Vivo Lipid Peroxidation and Platelet Activation in Cystic Fibrosis
Am. J. Respir. Crit. Care Med., October 1, 2000; 162(4): 1195 - 1201.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
R. DWORSKI, J. J. MURRAY, L. JACKSONROBERTS II, J. A. OATES, J. D. MORROW, L. FISHER, and J. R. SHELLER
Allergen-induced Synthesis of F2-Isoprostanes in Atopic Asthmatics . Evidence for Oxidant Stress
Am. J. Respir. Crit. Care Med., December 1, 1999; 160(6): 1947 - 1951.
[Abstract] [Full Text]

Home page
 Pharmacol. Rev.Home page
P. J. Barnes, K. F. Chung, and C. P. Page
Inflammatory Mediators of Asthma: An Update
Pharmacol. Rev., December 1, 1998; 50(4): 515 - 596.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Proc. Am. Thorac. Soc. Am. J. Respir. Cell Mol. Biol.
Copyright © 1997 American Thoracic Society